Arthritis, Psoriatic - 35 Studies Found Recruiting : Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis : Psoriatic Arthritis : 2015-03-16 : Biological: Secukinumab Anti IL-17a monoclonal antibody Completed : Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis : Psoriatic Arthritis : 2014-05-15 : Drug: UCB4940 40 mg Completed : Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment (WPAI)) : Psoriatic Arthritis : 2015-01-30 Completed : Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy : Arthritis, Psoriatic, Psoriasis : 2006-03-14 Recruiting : A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation : Psoriatic Arthritis : 2016-06-21 : Biological: adalimumab Drug: methotrexate Completed : TIght COntrol of Psoriatic Arthritis : Psoriatic Arthritis : 2010-04-15 : Drug: Intensive management or Tight control Active, not recruiting : PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis : Psoriatic Arthritis : 2010-09-29 : Drug: Apremilast 20mg Apremila Recruiting : Effect of Secukinumab in the Treatment of Psoriatic Arthritis : Psoriatic Arthritis : 2016-07-20 : Drug: Secukinumab All eligible patients registered into the study will receive four 150 - 300 mg subcuta Terminated : A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 : Psoriatic Arthritis : 2015-04-24 : Drug: ABT-122 Injection Completed : A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate : Psoriatic Arthritis : 2015-01-23 : Biological: adalimumab Double- <<< Previous | Next >>>
